Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.40 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 2/20 | 0.40 |
| ▸ | TGM2 | P21980 | 2/20 | 0.40 |
| ▸ | TGM1 | P22735 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691357 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6696661 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6692868 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL7212149 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6851928 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6690206 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6690204 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6690207 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6693784 | 0.90 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL6694472 | 0.90 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0812827-A1 | Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 1997-12-17 | — | — | EP | claimed |
| US-6815548-B2 | MINTERMEDIATE FOR PHARMACEUTICALS SUCH AS PAROXETINE USEFUL AS ANTIDEPRESSANTS, REPRESENTED BY THE GENERAL FORMULA (I): | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-11-09 | — | — | US | disclosed |
| EP-1394160-A1 | Process for preparing crystalline paroxetin hydrochloride | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1384720-A1 | Process for drying paroxetine hydrochloride | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1384711-A1 | Optical resolution of a piperidine derivative | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2004-01-28 | — | — | EP | disclosed |
| US-6610851-B1 | 1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-((3,4-methylene dioxyphenyl)oxymethyl)piperidine; reacting 4-(4-fluorophenyl)-3-hydroxymethylpiperidine with di-tert-butyl dicarbonate to form the carbamate; 3,4-methylenedioxyphenol | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20030144519-A1 | Process for preparing a piperidine derivative | SUMIKA FINE CHEMICALS CO., LTD. | 2003-07-31 | — | — | US | disclosed |
| US-6476227-B1 | Piperidine derivative and process for preparing the same | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| US-5948914-A | PREPARING 4-(4-FLUOROPHENYL)-3-HYDROXYMETHYLPIPERIDINE BY OPTICALLY RESOLVING WITH O-CHLOROTARTRANILIC ACID; CHEMICAL INTERMEDIATE FOR DRUGS | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0812827-A1 | Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144519-A1 | Process for preparing a piperidine derivative | TPH1, TPH2, HTR7 | SMN1; SMN2 2012/4885NPC1 2122/4885RAB9A 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.